TauRx Therapeutics Management Ltd has donated £2,500 to Aberdeen Sands, a volunteer-led group and part of Sands, who offer UK-wide support for everyone touched by pregnancy loss or the death of a baby before, during, or soon after birth.
More than £1,500 was raised by staff through a variety of events including quizzes, fantasy sports competitions and donations at social events, with the company rounding total up to £2,500. Pharmacovigilance Specialist Tom Hemmens went the extra mile, raising nearly £700 by taking part in the Cardiff Half Marathon, with colleagues paying for the privilege of adding to his running playlist.
TauRx People and Culture Director Lynn Rankin said: “We asked colleagues to suggest a charity we could support in 2025, and the runaway winner of our poll was Sands.
“The charity is particularly close to our colleague Lisa and her husband Ben whose daughter Nadine was stillborn at full-term in 2024. Their experience struck a chord with people across the company, and the decision to choose Sands as our beneficiary was a simple one in the end.
“It is the first time we have supported an organisation in this way and hope to raise as much for charity in 2026 as we did last year.”
Chloë Brunton-Dunn, corporate partnerships officer for Sands, said: “We are so grateful to the team from TauRx for supporting Sands. It’s been fantastic to see colleagues come together to raise funds, from quizzes to active challenges, the team have raised a brilliant amount with their efforts.
“Their fundraising will help to make a huge difference to our life-saving work at Sands, their impact will help us to reach more people with the support that they need after pregnancy loss or the death of a baby.”
TauRx, which is based within the First Aberdeen headquarters on the city’s King Street, has submitted a Marketing Authorisation Application for its drug to the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). If granted approval, the drug could be the first oral treatment for Alzheimer’s disease that targets the tau protein pathology.
